Listen to the interview with Bernard Zovighian, Chief Executive Officer, who explains Edwards Lifesciences' involvement in the 2023 edition of #EuroPCR.

Involved in a number of studies on mitral, tricuspid and aortic valves, he insists on the BENCHMARK late-breaking trial, which shows that, with streamlined TAVR procedures, hospitals can reduce length of stay and intensive care unit time, while maintaining the high efficacy of TAVR.

Watch this video to find out more!

Sponsored by Edwards Lifesciences

This video was recorded at #EuroPCR 2023.

View more interviews here:
[ Ссылка ]

#ICU
#TAVR

свернуть